Myriad Genetics to Present at Two Upcoming Healthcare Conferences

Rhea-AI Summary

Myriad Genetics, a leader in genetic testing and precision medicine, announced its participation in two major healthcare conferences. On Feb. 17, 2022, CFO R. Bryan Riggsbee will engage in a fireside chat at the virtual BTIG MedTech Conference at 12 p.m. ET. This will be followed by a discussion featuring President and CEO Paul J. Diaz and Riggsbee at the SVB Leerink Global Healthcare Conference on Feb. 18, 2022, at 11:20 a.m. ET. Interested parties can access live webcasts of these events via Myriad's investor information section at www.myriad.com.

SALT LAKE CITY, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be presenting at two upcoming healthcare conferences.

On Feb. 17, 2022, R. Bryan Riggsbee, chief financial officer, will participate in a fireside chat at the virtual BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference at 12 p.m. ET.

On Feb. 18, 2022, Paul J. Diaz, president and CEO, and Riggsbee will participate in a fireside chat at the 11^th annual SVB Leerink Global Healthcare Conference at 11:20 a.m. ET.

The presentations will be available through live audio webcast links in the investor information section of Myriad’s website at www.myriad.com.  

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the company's website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice, MyPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Prequel, Foresight, GeneSight, RiskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.

Media Contact:
Megan Manzari
(385) 318-3718
Megan.Manzari@myriad.com

Investor Contact:
Nathan Smith
(801) 505-5067
Nathan.Smith@myriad.com

FAQ

What events is Myriad Genetics participating in on February 2022?

Myriad Genetics will participate in two conferences: the BTIG MedTech Conference on February 17 and the SVB Leerink Global Healthcare Conference on February 18, 2022.

Who will represent Myriad Genetics at the BTIG MedTech Conference?

R. Bryan Riggsbee, the CFO, will represent Myriad Genetics at the BTIG MedTech Conference on February 17, 2022.

What time is Myriad's presentation at the SVB Leerink Conference?

The presentation at the SVB Leerink Global Healthcare Conference is scheduled for February 18, 2022, at 11:20 a.m. ET.

How can I watch the Myriad Genetics conference presentations?

The presentations can be watched live through audio webcasts available on Myriad Genetics' investor information section at www.myriad.com.

What is Myriad Genetics known for?

Myriad Genetics is known for its advancements in genetic testing and precision medicine, helping determine disease risk and guide treatment decisions.